{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:13:07Z","timestamp":1790230387062,"version":"4.1.0"},"reference-count":36,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,9,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Increasing fetal hemoglobin (HbF) provides clinical benefit in patients with sickle cell disease (SCD). We recently identified heme-regulated inhibitor (HRI, EIF2AK1), as a novel HbF regulator. Because HRI is an erythroid-specific protein kinase, it presents a potential target for pharmacologic intervention. We found that maximal HbF induction required &amp;gt;80% to 85% HRI depletion. Because it remains unclear whether this degree of HRI inhibition can be achieved pharmacologically, we explored whether HRI knockdown can be combined with pharmacologic HbF inducers to achieve greater HbF production and minimize potential adverse effects associated with treatments. Strongly cooperative HbF induction was observed when HRI depletion was combined with exposure to pomalidomide or the EHMT1\/2 inhibitor UNC0638, but not to hydroxyurea. Mechanistically, reduction in the levels of the HbF repressor BCL11A reflected the cooperativity of HRI loss and pomalidomide treatment, whereas UNC0638 did not modulate BCL11A levels. In conjunction with HRI loss, pomalidomide maintained its HbF-inducing activity at 10-fold lower concentrations, in which condition there were minimal observed detrimental effects on erythroid cell maturation and viability, as well as fewer alterations in the erythroid transcriptome. When tested in cells from patients with SCD, combining HRI depletion with pomalidomide or UNC0638 achieved up to 50% to 60% HbF and 45% to 50% HbF, respectively, as measured by high-performance liquid chromatography, and markedly counteracted cell sickling. In summary, this study provides a foundation for the exploration of combining future small-molecule HRI inhibitors with additional pharmacologic HbF inducers to maximize HbF production and preserve erythroid cell functionality for the treatment of SCD and other hemoglobinopathies.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020002475","type":"journal-article","created":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T18:59:33Z","timestamp":1600714773000},"page":"4560-4572","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["HRI depletion cooperates with pharmacologic inducers to elevate fetal hemoglobin and reduce sickle cell formation"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1483-1545","authenticated-orcid":false,"given":"Scott A.","family":"Peslak","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA;"},{"name":"Division of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2313-9710","authenticated-orcid":false,"given":"Eugene","family":"Khandros","sequence":"additional","affiliation":[{"name":"Division of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianjiang","family":"Lan","sequence":"additional","affiliation":[{"name":"Division of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly L.","family":"Geronimo","sequence":"additional","affiliation":[{"name":"Division of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3292-2873","authenticated-orcid":false,"given":"Jeremy D.","family":"Grevet","sequence":"additional","affiliation":[{"name":"Division of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2497-4291","authenticated-orcid":false,"given":"Osheiza","family":"Abdulmalik","sequence":"additional","affiliation":[{"name":"Division of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4681-1074","authenticated-orcid":false,"given":"Belinda M.","family":"Giardine","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Pennsylvania State University, State College, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6594-0245","authenticated-orcid":false,"given":"Cheryl A.","family":"Keller","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Pennsylvania State University, State College, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8427-6316","authenticated-orcid":false,"given":"Junwei","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4084-7516","authenticated-orcid":false,"given":"Ross C.","family":"Hardison","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Pennsylvania State University, State College, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0714-9612","authenticated-orcid":false,"given":"Gerd A.","family":"Blobel","sequence":"additional","affiliation":[{"name":"Division of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,9,21]]},"reference":[{"issue":"23","key":"2020092111384284300_B1","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","article-title":"Mortality in sickle cell disease. Life expectancy and risk factors for early death","volume":"330","author":"Platt","year":"1994","journal-title":"N Engl J Med"},{"issue":"5909","key":"2020092111384284300_B2","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1126\/science.1165409","article-title":"Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A","volume":"322","author":"Sankaran","year":"2008","journal-title":"Science"},{"issue":"6270","key":"2020092111384284300_B3","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1126\/science.aad3312","article-title":"Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin","volume":"351","author":"Masuda","year":"2016","journal-title":"Science"},{"issue":"9","key":"2020092111384284300_B4","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm.4170","article-title":"A genome-editing strategy to treat \u03b2-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition","volume":"22","author":"Traxler","year":"2016","journal-title":"Nat Med"},{"issue":"4","key":"2020092111384284300_B5","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41588-018-0085-0","article-title":"Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding","volume":"50","author":"Martyn","year":"2018","journal-title":"Nat Genet"},{"issue":"2","key":"2020092111384284300_B6","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.cell.2018.03.016","article-title":"Direct Promoter Repression by BCL11A Controls the Fetal to Adult Hemoglobin Switch","volume":"173","author":"Liu","year":"2018","journal-title":"Cell"},{"issue":"6399","key":"2020092111384284300_B7","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1126\/science.aao0932","article-title":"Domain-focused CRISPR screen identifies HRI as a fetal hemoglobin regulator in human erythroid cells","volume":"361","author":"Grevet","year":"2018","journal-title":"Science"},{"issue":"24","key":"2020092111384284300_B8","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1182\/blood.2020005301","article-title":"The HRI-regulated transcription factor ATF4 activates BCL11A transcription to silence fetal hemoglobin expression","volume":"135","author":"Huang","year":"2020","journal-title":"Blood"},{"issue":"23","key":"2020092111384284300_B9","doi-asserted-by":"crossref","first-page":"6909","DOI":"10.1093\/emboj\/20.23.6909","article-title":"Heme-regulated eIF2alpha kinase (HRI) is required for translational regulation and survival of erythroid precursors in iron deficiency","volume":"20","author":"Han","year":"2001","journal-title":"EMBO J"},{"issue":"11","key":"2020092111384284300_B10","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1172\/JCI32084","article-title":"The function of heme-regulated eIF2alpha kinase in murine iron homeostasis and macrophage maturation","volume":"117","author":"Liu","year":"2007","journal-title":"J Clin Invest"},{"issue":"22","key":"2020092111384284300_B11","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1182\/blood-2011-10-388132","article-title":"Heme-regulated eIF2\u03b1 kinase activated Atf4 signaling pathway in oxidative stress and erythropoiesis","volume":"119","author":"Suragani","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2020092111384284300_B12","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/blood-2017-08-799908","article-title":"HRI coordinates translation by eIF2\u03b1P and mTORC1 to mitigate ineffective erythropoiesis in mice during iron deficiency","volume":"131","author":"Zhang","year":"2018","journal-title":"Blood"},{"key":"2020092111384284300_B13","doi-asserted-by":"crossref","first-page":"e46976","DOI":"10.7554\/eLife.46976","article-title":"HRI coordinates translation necessary for protein homeostasis and mitochondrial function in erythropoiesis","volume":"8","author":"Zhang","year":"2019","journal-title":"eLife"},{"issue":"20","key":"2020092111384284300_B14","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia","volume":"332","author":"Charache","year":"1995","journal-title":"N Engl J Med"},{"issue":"3","key":"2020092111384284300_B15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1813598","article-title":"Hydroxyurea for children with sickle cell anemia in sub-Saharan Africa","volume":"380","author":"Tshilolo","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"2020092111384284300_B16","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1172\/JCI32322","article-title":"Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells","volume":"118","author":"Moutouh-de Parseval","year":"2008","journal-title":"J Clin Invest"},{"issue":"11","key":"2020092111384284300_B17","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1182\/blood-2015-09-667923","article-title":"Pomalidomide reverses \u03b3-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors","volume":"127","author":"Dulmovits","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2020092111384284300_B18","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood-2010-11-319137","article-title":"Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice","volume":"118","author":"Meiler","year":"2011","journal-title":"Blood"},{"issue":"16","key":"2020092111384284300_B19","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1182\/blood-2015-06-649087","article-title":"EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression","volume":"126","author":"Renneville","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2020092111384284300_B20","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1182\/blood-2015-02-629972","article-title":"Inhibition of G9a methyltransferase stimulates fetal hemoglobin production by facilitating LCR\/\u03b3-globin looping","volume":"126","author":"Krivega","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2020092111384284300_B21","doi-asserted-by":"crossref","first-page":"e0153767","DOI":"10.1371\/journal.pone.0153767","article-title":"Chemical Inhibition of Histone Deacetylases 1 and 2 Induces Fetal Hemoglobin through Activation of GATA2","volume":"11","author":"Shearstone","year":"2016","journal-title":"PLoS One"},{"issue":"28","key":"2020092111384284300_B22","doi-asserted-by":"crossref","first-page":"12617","DOI":"10.1073\/pnas.1006774107","article-title":"Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease","volume":"107","author":"Bradner","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"2020092111384284300_B23","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/ajh.24019","article-title":"Inactivation of HDAC1 or HDAC2 induces gamma globin expression without altering cell cycle or proliferation","volume":"90","author":"Esrick","year":"2015","journal-title":"Am J Hematol"},{"issue":"3","key":"2020092111384284300_B24","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/blood-2017-11-814335","article-title":"Metformin induces FOXO3-dependent fetal hemoglobin production in human primary erythroid cells","volume":"132","author":"Zhang","year":"2018","journal-title":"Blood"},{"issue":"22","key":"2020092111384284300_B25","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1182\/blood.2020005058","article-title":"Understanding heterogeneity of fetal hemoglobin induction through comparative analysis of F and A erythroblasts","volume":"135","author":"Khandros","year":"2020","journal-title":"Blood"},{"issue":"10","key":"2020092111384284300_B26","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1182\/bloodadvances.2019032318","article-title":"The E3 ligase adaptor molecule SPOP regulates fetal hemoglobin levels in adult erythroid cells","volume":"3","author":"Lan","year":"2019","journal-title":"Blood Adv"},{"issue":"6","key":"2020092111384284300_B27","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/ajh.23699","article-title":"Imaging flow cytometry for automated detection of hypoxia-induced erythrocyte shape change in sickle cell disease","volume":"89","author":"van Beers","year":"2014","journal-title":"Am J Hematol"},{"issue":"6","key":"2020092111384284300_B28","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1182\/blood.V81.6.1630.1630","article-title":"Hydroxyurea increases fetal hemoglobin in cultured erythroid cells derived from normal individuals and patients with sickle cell anemia or beta-thalassemia","volume":"81","author":"Fibach","year":"1993","journal-title":"Blood"},{"issue":"22","key":"2020092111384284300_B29","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1182\/blood-2014-01-548305","article-title":"Global transcriptome analyses of human and murine terminal erythroid differentiation","volume":"123","author":"An","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2020092111384284300_B30","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1715971","article-title":"A Phase 3 Trial of l-Glutamine in Sickle Cell Disease","volume":"379","author":"Niihara","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"2020092111384284300_B31","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2020092111384284300_B32","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ajh.25308","article-title":"Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis","volume":"94","author":"Kutlar","year":"2019","journal-title":"Am J Hematol"},{"issue":"6","key":"2020092111384284300_B33","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1903212","article-title":"A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease","volume":"381","author":"Vichinsky","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"2020092111384284300_B34","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1172\/JCI24141","article-title":"Heme-regulated eIF2alpha kinase modifies the phenotypic severity of murine models of erythropoietic protoporphyria and beta-thalassemia","volume":"115","author":"Han","year":"2005","journal-title":"J Clin Invest"},{"issue":"27","key":"2020092111384284300_B35","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2008.21.7356","article-title":"Pomalidomide is active in the treatment of anemia associated with myelofibrosis","volume":"27","author":"Tefferi","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11","key":"2020092111384284300_B36","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/blood-2012-08-450742","article-title":"Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib","volume":"121","author":"Richardson","year":"2013","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/18\/4560\/1758716\/advancesadv2020002475.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/18\/4560\/1758716\/advancesadv2020002475.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T18:59:47Z","timestamp":1600714787000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/18\/4560\/463777\/HRI-depletion-cooperates-with-pharmacologic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,21]]},"references-count":36,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2020,9,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020002475","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,21]]}}}